CU24638B1 - Suspensión oral con efecto antiulceroso y quimioprotector sobre el cáncer de colon - Google Patents

Suspensión oral con efecto antiulceroso y quimioprotector sobre el cáncer de colon

Info

Publication number
CU24638B1
CU24638B1 CU2020000007A CU20200007A CU24638B1 CU 24638 B1 CU24638 B1 CU 24638B1 CU 2020000007 A CU2020000007 A CU 2020000007A CU 20200007 A CU20200007 A CU 20200007A CU 24638 B1 CU24638 B1 CU 24638B1
Authority
CU
Cuba
Prior art keywords
suspension
microcrystalline cellulose
colon cancer
particle size
fatty alcohols
Prior art date
Application number
CU2020000007A
Other languages
English (en)
Other versions
CU20200007A7 (es
Inventor
Guerra Niurka Benitez
Canavaciolo Víctor Luis González
Castaño Sarahí Mendoza
Cuevas Vivian Molina
Yera Ámbar Oyarzábal
Leyes Eduardo Antonio Rodríguez
Zamora Reynerio Rodríguez
Murillo Roxana Vicente
Original Assignee
Centro Nac De Investigaciones Cientificas
Empresa Laboratorio Farm Liquidos Orales Medilip
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Nac De Investigaciones Cientificas, Empresa Laboratorio Farm Liquidos Orales Medilip filed Critical Centro Nac De Investigaciones Cientificas
Priority to CU2020000007A priority Critical patent/CU24638B1/es
Priority to KR1020227030797A priority patent/KR20230129150A/ko
Priority to NZ790793A priority patent/NZ790793B2/en
Priority to PCT/CU2020/050008 priority patent/WO2021155871A1/es
Priority to AU2020427452A priority patent/AU2020427452B2/en
Priority to US17/797,022 priority patent/US20230071637A1/en
Priority to PH1/2022/551969A priority patent/PH12022551969A1/en
Priority to JP2022547267A priority patent/JP2023518659A/ja
Priority to CN202080095526.6A priority patent/CN115087432A/zh
Priority to CA3169969A priority patent/CA3169969C/en
Priority to EP20917601.5A priority patent/EP4101444A4/en
Publication of CU20200007A7 publication Critical patent/CU20200007A7/es
Publication of CU24638B1 publication Critical patent/CU24638B1/es
Priority to JP2024180594A priority patent/JP2025013849A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A61K35/644—Beeswax; Propolis; Royal jelly; Honey
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Insects & Arthropods (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Animal Husbandry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>Se revela una nueva composición farmacéutica que consiste en una suspensión acuosa oral para la prevención y tratamiento de las úlceras gástricas y el cáncer de colón. Esta suspensión se desarrolló debido a la necesidad de contar con una forma farmacéutica cuya eficacia gasoprotectora fuera superior a las reportadas para la tableta con 50 mg de alcoholes grasos y para la suspensión de celulosa microcristalina a 12 %. La suspensión se caracteriza por contener un extracto purificado con los alcoholes grasos de la cera de abejas, celulosa microcristalina y excipientes aceptados por la industria farmacéutica, donde el extracto de alcoholes grasos se somete a un proceso de disminución de tamaño de partícula a < 1, 5 micrómetros en presencia de un agente emulsionante a > 1000 rpm. La mezcla de dicho ingrediente activo, en el tamaño de partícula especificado anteriormente, con celulosa microcristalina en la proporción y concentración en que se formulan, hace que estos componentes actúen de forma sinérgica, confiriéndole potentes efectos antiulcerosos y quimioprotectores a esta composición.</p>
CU2020000007A 2020-02-03 2020-02-03 Suspensión oral con efecto antiulceroso y quimioprotector sobre el cáncer de colon CU24638B1 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CU2020000007A CU24638B1 (es) 2020-02-03 2020-02-03 Suspensión oral con efecto antiulceroso y quimioprotector sobre el cáncer de colon
US17/797,022 US20230071637A1 (en) 2020-02-03 2020-12-14 Oral suspension with antiulcerous and chemoprotective effect on colon cancer and preparation method thereof
NZ790793A NZ790793B2 (en) 2020-12-14 Oral suspension with anti-ulcerous and chemoprotective effect on colon cancer and preparation method thereof
PCT/CU2020/050008 WO2021155871A1 (es) 2020-02-03 2020-12-14 Suspensión oral con efecto antiulceroso y quimioprotector sobre el cáncer de colon y método para su preparación
AU2020427452A AU2020427452B2 (en) 2020-02-03 2020-12-14 Oral suspension with anti-ulcerous and chemoprotective effect on colon cancer and preparation method thereof
KR1020227030797A KR20230129150A (ko) 2020-02-03 2020-12-14 결장암에 대한 항궤양 및 화학보호 효과를 갖는 경구 현탁액 및 그의 제조 방법
PH1/2022/551969A PH12022551969A1 (en) 2020-02-03 2020-12-14 Oral suspension with anti-ulcerous and chemoprotective effect on colon cancer and preparation method thereof
JP2022547267A JP2023518659A (ja) 2020-02-03 2020-12-14 結腸癌に対する抗潰瘍性及び化学的防御効果を有する経口懸濁液及びその調製方法
CN202080095526.6A CN115087432A (zh) 2020-02-03 2020-12-14 具有抗溃疡和对结肠癌的化学保护性作用的口服悬浮液及其制备方法
CA3169969A CA3169969C (en) 2020-02-03 2020-12-14 Oral suspension with antiulcerous and chemoprotective effect on colon cancer and method for its preparation
EP20917601.5A EP4101444A4 (en) 2020-02-03 2020-12-14 ORAL SUSPENSION HAVING ANTIULCARESOUS AND CHEMOPROTECTIVE EFFECT ON COLON CANCER AND METHOD FOR THE PRODUCTION THEREOF
JP2024180594A JP2025013849A (ja) 2020-02-03 2024-10-16 結腸癌に対する抗潰瘍性及び化学的防御効果を有する経口懸濁液及びその調製方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2020000007A CU24638B1 (es) 2020-02-03 2020-02-03 Suspensión oral con efecto antiulceroso y quimioprotector sobre el cáncer de colon

Publications (2)

Publication Number Publication Date
CU20200007A7 CU20200007A7 (es) 2021-09-07
CU24638B1 true CU24638B1 (es) 2023-01-16

Family

ID=77199690

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000007A CU24638B1 (es) 2020-02-03 2020-02-03 Suspensión oral con efecto antiulceroso y quimioprotector sobre el cáncer de colon

Country Status (9)

Country Link
US (1) US20230071637A1 (es)
EP (1) EP4101444A4 (es)
JP (2) JP2023518659A (es)
KR (1) KR20230129150A (es)
CN (1) CN115087432A (es)
AU (1) AU2020427452B2 (es)
CU (1) CU24638B1 (es)
PH (1) PH12022551969A1 (es)
WO (1) WO2021155871A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22229A1 (es) * 1992-09-29 1996-01-31 Dalmer Lab Sa Policosanol, una mezcla de alcoholes alifaticos primarios superiores para hipergregabilidad plaquetaria, los accidentes isquemicos, trombosis e incluso efectividad contra ulceras gastricas quimicamente inducidas y su proceso de obtencion de la caña de azucar. el tratamiento de complicaciones ateroscleroticas tales como la
CU22412A1 (es) 1993-11-09 1996-01-31 Dalmer Lab Sa Una mezcla natural compuesta por alcoholes alifaticos primarios superiores obtenidos de la cera de abejas para el tratamiento de las ulceras gastricas y duodenales que presenta tambien actividad antiinflamatoria
US6465526B1 (en) * 1994-11-07 2002-10-15 Laboratories Dalmer Sa Natural mixture composed of higher primary aliphatic alcohols obtained from bee wax for the treatment of gastric and duodenal ulcers that also present antiinflamatory activity
CN1125096A (zh) * 1994-12-23 1996-06-26 戴默实验室股份公司 由来自蜂蜡的高级脂肪伯醇组成的天然混合物
CU22723A1 (es) * 1997-04-02 2002-02-28 Dalmer Lab Sa Mezcla de ácidos grasos primarios de alto peso molecular obtenidos de la cera de cana de azúcar y sus usos farmacéuticos
US6225354B1 (en) * 1999-06-21 2001-05-01 Cholesterol Control Laboratories, Inc. High molecular weight primary aliphatic alcohols obtained from beeswax and pharmaceutical use thereof
US6565873B1 (en) * 2000-10-25 2003-05-20 Salvona Llc Biodegradable bioadhesive controlled release system of nano-particles for oral care products
AR047948A1 (es) * 2003-11-21 2006-03-15 Schering Corp Formulaciuones de inhibidores de la fosfodiesterasa v
US20050266031A1 (en) * 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
JP2014177437A (ja) * 2013-03-15 2014-09-25 Tottori Univ セルロースナノファイバーを含有する炎症性腸疾患治療剤

Also Published As

Publication number Publication date
KR20230129150A (ko) 2023-09-06
WO2021155871A1 (es) 2021-08-12
EP4101444A1 (en) 2022-12-14
AU2020427452A1 (en) 2022-09-22
US20230071637A1 (en) 2023-03-09
AU2020427452B2 (en) 2023-11-23
NZ790793A (en) 2025-02-28
PH12022551969A1 (en) 2023-10-09
CN115087432A (zh) 2022-09-20
JP2025013849A (ja) 2025-01-28
EP4101444A4 (en) 2024-02-28
JP2023518659A (ja) 2023-05-08
CA3169969A1 (en) 2021-08-12
CU20200007A7 (es) 2021-09-07

Similar Documents

Publication Publication Date Title
CL2019000209A1 (es) Formulación novedosa administrable por la vía oral.
AR082024A1 (es) Formulacion de anticuerpo contra ox40l humano
MX2012005677A (es) Formulaciones parentales de derivados de gemcitabina.
CA3008019A1 (en) Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
MX372770B (es) Composiciones para comprimidos bucodispersables que contienen corticosteroides para esofagitis eosinofílica.
JP2021532145A (ja) 眼を治療するための組成物及び方法
JP2013512275A (ja) Ｈｉｖ感染予防用ヒドロキシチロソール及び誘導体の局所使用
AR114216A1 (es) Composiciones oftálmicas de compuestos de bencimidazol para uso único diario
Tritten et al. Nitazoxanide: In vitro and in vivo drug effects against Trichuris muris and Ancylostoma ceylanicum, alone or in combination
KR20210038635A (ko) 눈 치료용 조성물 및 방법
CN112804990B (zh) 一种脂质体滴眼液及其在治疗干眼症中的应用
CN1323660C (zh) 治疗病毒性皮肤和肿瘤疾病的药物
CN113893240A (zh) 包含15-hepe的组合物和其使用方法
JPWO2021003341A5 (es)
CU24638B1 (es) Suspensión oral con efecto antiulceroso y quimioprotector sobre el cáncer de colon
JP2021080254A (ja) 眼を治療するための組成物及び方法
DE102009012465A1 (de) Pharmazeutische Zusammensetzung zur Prophylaxe und Behandlung der Arteriosklerose, sowie zur Schmerzbekämpfung und zur Entzündungshemmung
AR123872A1 (es) Comprimido de desintegración oral, procedimiento de preparación del mismo, procedimiento para prevenir o tratar enfermedades y uso del mismo
US11298393B2 (en) Composition comprising a mixture of an extract and bentonite
WO2016086280A1 (pt) Composição dermatológica e seu uso
RU2010125503A (ru) СОДЕРЖАЩАЯ КОМБИНАЦИЮ ЦЕОЛИТ/ВОДОРОСЛИ ИЛИ ЦЕОЛИТ/ЭМУЛЬСИЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ЛЕЧЕНИЯ СПИДа
RU2780109C1 (ru) Противовоспалительные глазные капли для домашних и сельскохозяйственных животных
CN1555257A (zh) 家禽腹水预防剂
AR127582A1 (es) Métodos para el tratamiento del cáncer
CO6241114A2 (es) Composicion farmaceutica que comprende la combinacion del agente antimicrobiano ciprofloxacino y el agente antioxidante acido ascorbico para el tratamiento de infecciones urinarias